Beximco Pharmaceuticals Limited has changed the name of the recently acquired subsidiary, Sanofi Bangladesh Limited, to Synovia Pharma PLC, with effect from 1 April, 2022.
Sanofi Bangladesh Limited was part of the global biopharmaceutical company Sanofi S.A. before the acquisition of a majority stake in the company (54.6%) by Beximco Pharma on 1 October 2021.
The change of name has been made in compliance with the terms of the Share Purchase Agreement between the Company and the Sellers.
The name “Synovia” is derived from the French word Synergie, meaning “collaboration” and the Latin word Via, meaning “path”.
Synovia Pharma will continue to manufacture, market and import Sanofi S.A. products, ensuring continued supply for patients in Bangladesh across therapeutic areas such as cardiology, diabetes, oncology, dermatology and CNS.
These treatments, as well as opportunities to introduce Sanofi’s future global brands, will drive future growth of Beximco Pharmaby expanding its addressable market and reinforcing the company’s commitment to ensure access to breakthrough therapies and affordable medicines.
